Teva Says GSK Skinny Label Win Will Have 'Seismic' Impact
By Dani Kass · October 7, 2021, 5:46 PM EDT
The Federal Circuit's second holding that Teva induced doctors to infringe a patent for GlaxoSmithKline's drug Coreg, despite allegedly carving out the only patented-protected treatment from its label, will have a...
To view the full article, register now.